Market revenue in 2023 | USD 264.5 million |
Market revenue in 2030 | USD 394.2 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Transvenous implantable cardioverter-defibrillators |
Fastest growing segment | Subcutaneous Implantable Cardioverter Defibrillators |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Transvenous Implantable Cardioverter-Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, BIOTRONIK, Boston Scientific Corp, MicroPort Scientific Corp, LivaNova PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to implantable cardioverter defibrillators market will help companies and investors design strategic landscapes.
Transvenous implantable cardioverter-defibrillators was the largest segment with a revenue share of 90.89% in 2023. Horizon Databook has segmented the Germany implantable cardioverter defibrillators market based on transvenous implantable cardioverter-defibrillators, subcutaneous implantable cardioverter defibrillators covering the revenue growth of each sub-segment from 2018 to 2030.
According to the Deutsches Zentrum für Herz-Kreislaufforschung e.V., around 65,000 people in the country die due to SCA every year, which also represents 20% of all deaths in the country due to CVDs. Furthermore, as per MedTech Europe data 2020, an estimated 189 units of biventricular devices per million population were implanted in Germany.
Furthermore, the region houses one of the key ICD market players, Biotronik, which increases the country's access to ICDs. In addition, the company’s research to treat different forms of heart diseases with scientific advancements aid market growth.
For instance, in June 2023, the company published a result stating that its early antitachycardia pacing (eATP) feature was found helpful in mitigating ventricular tachycardia in the VF zone than other traditional ATPs, while simultaneously reducing unnecessary shocks.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany implantable cardioverter defibrillators market , including forecasts for subscribers. This country databook contains high-level insights into Germany implantable cardioverter defibrillators market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account